Whitepapers

This asset outlines the comprehensive support and guidance offered by the FAS team for optimizing monoclonal antibody (mAb) manufacturing processes using the Efficient-Pro medium and feeds. Readers will learn about the tailored assistance provided at every stage, including troubleshooting, recommendations

Learn about how Efficient-Pro Medium and Feeds elevate productivity in CHO-K1, CHO-S, and DG44 cells for bioproduction in this comprehensive content piece.

Biopharmaceutical companies are increasingly partnering with CDMOs equipped with technologies and expertise to support analytical testing during process development. The level of complexity required to develop and manufacture cell and gene therapies has increased, including the use of various raw materials, custom reagents, and tailored approaches for managing complex diseases.

The Gibco Efficient-Pro Medium and Feeds Evaluation Guide provides insights into enhancing monoclonal antibody manufacturing workflows. Offering improved titers, viability, and protein quality in CHO cell lines, it introduces a comprehensive evaluation process for maximizing productivity. Explore this asset for detailed step-by-step guidance and troubleshooting tips

Discover how the Gibco™ Efficient-Pro™ system boosts productivity, enhances cell viability, and ensures superior product quality with minimal impurities. Packed with detailed fed-batch study results, this guide offers actionable insights and practical tips to optimize your bioproduction processes, ensuring you achieve higher yields and consistent, high-quality outcomes. Dive into this indispensable asset to elevate your manufacturing workflow to the next level.

In this asset, you will discover how the Gibco Efficient-Pro system can revolutionize your mAb manufacturing workflow. It provides insights into optimizing CHO cell productivity, enhancing product titers and protein quality, streamlining process efficiency, and leveraging a reliable supply network.

Learn about the importance of considering human factors testing beyond the initial validation phase. Through two case studies, it illustrates how seemingly minor product changes can trigger regulatory scrutiny. The message is clear: proactive testing and expert guidance are essential to navigate regulatory requirements effectively.

Raw material testing is critical for drug development, ensuring safety and efficacy. Look for a partner with extensive compendial experience, ample capacity, fast turnaround times, digital capabilities, modality expertise, global presence, regulatory compliance, and a focus on value.

EBPT Toronto expands Eurofins BioPharma Product Testing's North American presence, offering comprehensive product testing services in Toronto. With a focus on cGMP compliance, the facility provides chemistry, microbiology, and regulatory consulting services, including testing for controlled substances. It ensures consistent quality across its network, prioritizing customer satisfaction and regulatory compliance throughout the drug development process.

The Toxicology Team in Lancaster now offers expanded services including biological evaluations to help clients with biocompatibility strategies and regulatory compliance. We provide tailored consulting for specific needs like mitigating biological risks due to product changes or failed tests. Each project is evaluated individually, ensuring customized solutions and enhanced client value.

Eurofins BioPharma Product Testing in Lancaster, PA, is a leader in ensuring the quality and safety of cell banks used in biomanufacturing. Certified by regulatory agencies like the FDA and TGA, EBPT's Cell Banking Department operates under stringent quality standards. We employ controlled processes, including employee training and contamination control, to maintain quality. With global certification, EBPT's laboratories are equipped to meet manufacturing needs worldwide.

EBPT provides expert support for Environmental Monitoring programs, ensuring clean and controlled manufacturing environments. Our services include designing monitoring programs, collecting samples, and analyzing data using advanced equipment. With locations across the U.S., EBPT offers nationwide support to pharmaceutical and medical device clients with standardized practices and specialized expertise.

Having a robust Cell Line Development (CLD) strategy is the foundation of biologic production that can propel a project, helping to streamline production while mitigating risk. A tailored and optimized cell line can be instrumental in overcoming development and manufacturing challenges and achieving a competitive advantage in the market with streamlined manufacturing processes. In this eBook, Bora Biologics describes how a robust CLD strategy can help biologics developers anticipate and overcome challenges and streamline production.

See how stability of a formulation in Woodstock Sterile Solutions’ primary container design compares to glass vials.

Is blow-fill-seal technology the right fit for your pharmaceutical product? Download our checklist to find out. 

Well-designed analytical testing of biologics is essential during every stage of biopharmaceutical development to ensure the safety and quality of the drug and provides an important feedback loop during development. In this article, Bora Biologics delves into the significance of rigorous analytical testing, highlighting strategies to meet regulatory standards and enhance processes effectively.

Complex formulation development presents unique challenges. Download this white paper for three key considerations.